⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8906050 | 0.94 | — | — | |
| SCHEMBL8058196 | 0.94 | — | — | |
| SCHEMBL18840093 | 0.88 | — | — | |
| SCHEMBL8675941 | 0.88 | — | — | |
| Water SCHEMBL2574390 | 0.88 | — | — | |
| SCHEMBL10766764 | 0.88 | — | — | |
| SCHEMBL2535798 | 0.88 | — | — | |
| SCHEMBL9443297 | 0.88 | MEN1 (0.67) | — | |
| SCHEMBL11658537 | 0.88 | — | — | |
| Ammonia Solution, Strong SCHEMBL22462079 | 0.88 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-214598667-U | Silver nitrate blending device for lead removal and purification of silver nitrate | 夏县运力化工有限公司 | 2021-11-05 | — | — | CN | disclosed |
| EP-2270018-A1 | Antitumoral analogs | Pharma Mar, S.A. (ES) | 2011-01-05 | — | — | EP | disclosed |
| US-7763615-B2 | Ecteinascidin analogs for use as antitumour agents | PHARMA MAR, S.A. (ES) | 2010-07-27 | — | — | US | disclosed |
| EP-1414828-B9 | ANTITUMORAL ANALOGS | PHARMA MAR SA (ES) | 2008-02-20 | — | — | EP | disclosed |
| EP-1414828-B1 | ANTITUMORAL ANALOGS | PHARMA MAR SA (ES) | 2007-10-03 | — | — | EP | disclosed |
| EP-1806349-A1 | ANTITUMORAL ANALOGS | Pharma Mar, S.A. (ES) | 2007-07-11 | — | — | EP | disclosed |
| US-20060128711-A1 | derivatives of ecteinascidins, particularly ecteinascidin 736, used for the treatment of lung, colon, kidney, prostate, cervical, ovarian, breast or pancreatic cancer, leukaemia or melanoma in mammals; reduced systemic toxicity and improved pharmacokinetics | PHARMA MAR, S.A. (ES) | 2006-06-15 | — | — | US | disclosed |
| EP-1414828-A1 | ANTITUMORAL ANALOGS | PHARMA MAR, S.A. (ES) | 2004-05-06 | — | — | EP | disclosed |
| WO-2003014127-A1 | ANTITUMORAL ANALOGS | PHARMA MAR, S.A. (ES) | 2003-02-20 | — | — | WO | disclosed |